98 related articles for article (PubMed ID: 8410065)
1. Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Kuiper MA; Konings CH; Bergmans PL; Wolters EC
J Neurol Sci; 1993 Jul; 117(1-2):41-5. PubMed ID: 8410065
[TBL] [Abstract][Full Text] [Related]
2. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Husain M; Shukla R; Dikshit M; Maheshwari PK; Nag D; Srimal RC; Seth PK; Khanna VK
Neurochem Res; 2009 Aug; 34(8):1427-32. PubMed ID: 19259810
[TBL] [Abstract][Full Text] [Related]
3. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Kuhn W; Müller T; Gerstner A; Winkel R; Goetz ME
Can J Neurol Sci; 1998 Aug; 25(3):249-51. PubMed ID: 9706728
[TBL] [Abstract][Full Text] [Related]
4. Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation.
Jarman J; Glover V; Sandler M; Turjanski N; Stern G
J Neural Transm Park Dis Dement Sect; 1993; 5(1):1-4. PubMed ID: 8439389
[TBL] [Abstract][Full Text] [Related]
5. Platelet monoamine oxidase B activity in parkinsonian patients.
Bonuccelli U; Piccini P; Del Dotto P; Pacifici GM; Corsini GU; Muratorio A
J Neurol Neurosurg Psychiatry; 1990 Oct; 53(10):854-5. PubMed ID: 2266365
[TBL] [Abstract][Full Text] [Related]
6. Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls.
Finch CC; Ho SL; Williams AC; Billett EE
Prog Brain Res; 1995; 106():85-90. PubMed ID: 8584677
[No Abstract] [Full Text] [Related]
7. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Zeller EA; Boshes B; Arbit J; Bieber M; Blonsky ER; Dolkart M; Huprikar SV
J Neural Transm; 1976; 39(1-2):63-77. PubMed ID: 978197
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
Checkoway H; Costa LG; Woods JS; Castoldi AF; Lund BO; Swanson PD
J Neural Transm Park Dis Dement Sect; 1992; 4():283-90. PubMed ID: 1388699
[TBL] [Abstract][Full Text] [Related]
10. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Danielczyk W; Streifler M; Konradi C; Riederer P; Moll G
Acta Psychiatr Scand; 1988 Dec; 78(6):730-6. PubMed ID: 3223331
[TBL] [Abstract][Full Text] [Related]
11. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
[TBL] [Abstract][Full Text] [Related]
12. Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Ahlskog JE; Uitti RJ; Tyce GM; O'Brien JF; Petersen RC; Kokmen E
J Neurol Sci; 1996 Mar; 136(1-2):162-8. PubMed ID: 8815165
[TBL] [Abstract][Full Text] [Related]
13. Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
van Kempen GM; Janjua R; Roos RA
Clin Neurol Neurosurg; 1995 May; 97(2):131-3. PubMed ID: 7656485
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity of human platelet monoamine oxidase B activity Parkinson's and Alzheimer's disease.
Fitzgerald DH; Tipton KF; Anderson MC; Lawlor B
Biochem Soc Trans; 1996 Feb; 24(1):63S. PubMed ID: 8674739
[No Abstract] [Full Text] [Related]
15. Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Zellner M; Baureder M; Rappold E; Bugert P; Kotzailias N; Babeluk R; Baumgartner R; Attems J; Gerner C; Jellinger K; Roth E; Oehler R; Umlauf E
J Proteomics; 2012 Apr; 75(7):2080-92. PubMed ID: 22270014
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study.
Otsuka M; Ichiya Y; Kuwabara Y; Hosokawa S; Sasaki M; Yoshida T; Fukumura T; Kato M; Masuda K
J Neurol Sci; 1996 Dec; 144(1-2):77-83. PubMed ID: 8994107
[TBL] [Abstract][Full Text] [Related]
17. The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.
Costa-Mallen P; Checkoway H; Fishel M; Cohen AW; Smith-Weller T; Franklin GM; Swanson PD; Costa LG
Neurosci Lett; 2000 Jan; 278(1-2):33-6. PubMed ID: 10643794
[TBL] [Abstract][Full Text] [Related]
18. MAO-B and Parkinson's disease.
Sturman SG; Steventon GB; Waring RH; Williams AC
Mov Disord; 1990; 5(4):338-9. PubMed ID: 2259360
[No Abstract] [Full Text] [Related]
19. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
20. [Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)].
Schneider G; Oepen H; von Wedel HR
Arch Psychiatr Nervenkr (1970); 1981; 230(1):5-15. PubMed ID: 6455104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
